Bioptimus is considered a spin-off from Owkin and has signed a partnership with Amazon Web Services for training its model in Amazon's data centers. The startup aims to improve disease diagnosis, precision medicine, and help create new biomolecules for medical or environmental use. With the funding, Bioptimus will now focus on developing its AI model and exploring its potential applications in the biotech research community.
Key takeaways:
- Bioptimus, a new generative AI startup based in Paris, is focusing exclusively on biology, using AI models to deal with sensitive clinical data.
- The startup is raising a $35 million seed round led by Sofinnova Partners, with participation from Bpifrance’s Large Venture fund, Frst, Cathay Innovation, Headline, Hummingbird, NJF Capital, Owkin, Top Harvest Capital and Xavier Niel.
- Bioptimus is a sort of spin-off company from Owkin, and will leverage Owkin's multimodal patient data to train its foundational model.
- Bioptimus has signed a partnership with Amazon Web Services and plans to use the funding to improve disease diagnosis, precision medicine, and help create new biomolecules for medical or environmental use.